B
Bull
Bull · 25%OGN
$9.72
Precio del escenario
$13.760
0.000 (0.00%)Al cierre
Loading chart…
- High
- 13.770
- Open
- 13.760
- VWAP
- 13.76
- Vol
- 2.71M
- Mkt Cap
- 5.30B
- Low
- 13.760
- Amount
- 37.28M
- EV/EBITDA, TTM
- 6.72
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
AI analysis of Organon & Co (OGN)
buyOrganon & Co (OGN) is a good buy right now at $13.76, especially considering its forward P/E of 5.09, which indicates strong earnings potential relative to its price. Additionally, the stock has shown a remarkable year-to-date change of +90.06%, reflecting strong market interest. The main risk is its recent net income fluctuations, including a negative net income of -205 million in Q4 2025, which could affect future performance.
Métricas de valoración
The current forward P/E ratio for Organon & Co (OGN) is 5.09, compared to its 5-year average forward P/E of 4.84.
Alphio AI Price Scenarios for OGN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding OGN
Cronología de eventos
Noticias
5.008-11NewsfilterMIUDELLA Launches Training and Certification Program for Healthcare Providers
- 8.007-31seekingalpha
Organon Declares Quarterly Dividend of $0.02 per Share
9.007-24NewsfilterVTAMA Cream Shows Breakthrough Data in Pediatric Eczema Treatment
- 9.507-16Newsfilter
Organon Plans to Release Q2 2026 Financial Results
8.507-10GlobenewswireOrogen Royalties Inc Qualifies for OTCQX Market Trading
OGN FAQ — answered by Alphio AI
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Organon & Co (OGN) is a good buy right now at $13.76, especially considering its forward P/E of 5.09, which indicates strong earnings potential relative to its price. Additionally, the stock has shown a remarkable year-to-date change of +90.06%, reflecting strong market interest. The main risk is its recent net income fluctuations, including a negative net income of -205 million in Q4 2025, which could affect future performance.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.